Aclidinium + formoterol

Trade Name:

Duaklir Genuair

Manufacturer/Distributor:

AstraZeneca Canada Inc.

www.astrazeneca.ca

Classification:

Bronchodilator combination - LAMA plus LABA

ATC Class:

R03AL - Adrenergics with anticholinergics

Status:

active

Notice of Compliance (yyyy/mm/dd):

2015/04/02

Date Marketed in Canada (yyyy/mm/dd):

2015/07/09

Presentation:

Powder for Inhalation: aclidinium 400 mcg plus formoterol 12 mcg. DIN: 02439530

Comments:

Combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA) for the long term maintenance bronchodilator treatment of patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

Keywords:

aclidinium

Keywords:

formoterol

Keywords:

bronchodilator agents

Keywords:

emphysema

Keywords:

lung disease: obstructive

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Enzalutamide	Xtandi	Antineoplastic agent	2013/06/07
Venetoclax	Venclexta	Antineoplastic agent	2016/10/31
Ixazomib	Ninlaro	Antineoplastic agent	2016/09/21
Avelumab	Bavencio	Antineoplastic agent	2017/12/18
Brigatinib	Alunbrig	Antineoplastic agent	2018/07/26
Ribociclib	Kisqali	Antineoplastic agent	2018/11/26
Cabozantinib	Cabometyx	Antineoplastic agent	2018/09/14
Cemiplimab	Libtayo	Antineoplastic agent	2019/05/24
Alpelisib	Piqray	Antineoplastic agent	2020/03/11
Axicabtagene ciloleucel	Yescarta	Antineoplastic agent	2019/11/27
Trastuzumab deruxtecan	Enhertu	Antineoplastic agent	2021/04/15
Entrectinib	Rozlytrek	Antineoplastic agent
Gilteritinib	Xospata	Antineoplastic agent	2020/02/03
Glasdegib	Daurismo	Antineoplastic agent	2020/08/10
Larotrectinib	Vitrakvi	Antineoplastic agent	2019/07/10
Niraparib	Zejula	Antineoplastic agent	2020/01/09
Sonidegib	Odomzo	Antineoplastic agent	2020/06/11
Tucatinib	Tukysa	Antineoplastic agent	2020/10/08
Enasidenib	IDHIFA	Antineoplastic agent / IDH2 Inhibitor	2019/02/27
Daratumumab	Darzalex SC	Antineoplastic agent, monoclonal antibody	2020/08/12
Isatuximab	Sarclisa	Antineoplastic agent, monoclonal antibody	2020/07/03
Pomalidomide	Pomalyst	Antineoplastic agent; immunmodulator	2014/02/24
Brolucizumab	Beovu	Antineovascularisation agent	2020/05/15
Rotigotine	Neupro	Antiparkinsonian agent / Dopamine agonist	2013/09/12
Aluminum chloride hexahydrate	Hydrosal gel	Antiperspirant
Prasugrel	Effient	Antiplatelet agent	2020/01/31
Aripiprazole	Abilify	Antipsychotic agent	2009/07/03
Paliperidone palmitate	Invega Sustenna	Antipsychotic agent	2010/07/28
Paliperidone	Invega	Antipsychotic agent	2007/10/02
Brexpiprazole	Rexulti	Antipsychotic agent	2017/04/20
Elvitegravir + Cobicistat + Emtricitabine + Tenofovir disoproxil fumarate	Stribild	Antiretroviral agent	2012/12/20
Emtricitabine + tenofovir	Descovy	Antiretroviral agent	2016/06/03
Cabotegravir	Vocabria	Antiretroviral agent	2020/03/19
Cabotegravir + rilpivirine	Cabenuva	Antiretroviral agent	2020/03/19
Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide	Genvoya	Antiretroviral agents	2016/02/03
Caplacizumab	Cablivi	Antithrombotic agent	2020/09/04